Saizen 24.i.u. 8mg

Saizen 24.i.u. 8mg

Recombinant growth hormone is identical in composition and effects of human growth hormone pituitary. It is a polypeptide comprising 191 amino acids. The biological activity of about 24 IU / 8 mg. It stimulates skeletal growth and weight gain; Stimulates the transport of amino acids into the cell, accelerating the synthesis of intracellular proteins and showing the effects of this anabolic mode. Causes a delay in the body of nitrogen, mineral salts (calcium, phosphorus, and sodium) and liquid. Increased blood glucose.

Dosage:

Saizen 8 mg click.easy is intended for multiple dose use. Saizen dosage should be individualised for each patient based on body surface area or on body weight.

Children and adolescents:

• Growth failure due to inadequate endogenous growth hormone secretion:

0.7-1.0 mg/m² body surface area per day or 0.025-0.035 mg/kg body weight per day by subcutaneous administration.

• Growth failure in girls due to gonadal dysgenesis (Turner syndrome):

1.4 mg/m² body surface area per day or 0.045-0.050 mg/kg body weight per day by subcutaneous administration. Concomitant therapy with non-androgenic anabolic steroids in patients with Turner syndrome can enhance the growth response.

• Growth failure in prepubertal children due to chronic renal failure (CRF):

1.4 mg/m² body surface area per day, approximately equal to 0.045-0.050 mg/kg body weight per day by subcutaneous administration.

• Growth failure in short children born small for gestational age (SGA):

The recommended daily dose is 0.035 mg/kg body weight (or 1 mg/m²/day, equal to 0.1 IU kg/day or 3 IU m²/day) per day, by subcutaneous administration.

Treatment should be discontinued when the patient has reached a satisfactory adult height, or the epiphyses are fused.

For growth disturbance in short children born SGA, treatment is usually recommended until final height is reached. Treatment should be discontinued after the first year if height velocity SDS is below +1. Treatment should be discontinued when final height is reached (defined as height velocity <2 cm/year), and if confirmation is required if bone age is >14 years (girls) or >16 years (boys), corresponding to closure of the epiphyseal growth plates.

Adults:

• Growth hormone deficiency in adults

At the start of somatropin therapy, low doses of 0.15-0.3 mg are recommended, given as a daily subcutaneous injection. The dose should be adjusted stepwise, controlled by Insulin-like Growth Factor 1 (IGF-1) values. The recommended final growth hormone dose seldom exceeds 1.0 mg/day. In general the lowest efficacious dose should be administered. In older or overweight patients, lower doses may be necessary. Patients with renal or hepatic impairment.

Several side effects may be experienced by patients who buy Saizen 24.i.u.

Some of the minor side effects in children are:

• Headaches;
• mild rash;
• pain in joints and muscles minor;
• Itching sensation at the injection site;
• Swelling of the hands and feet;

Some important side effects of Saizen 24.i.u. observed in children are:

• Severe allergic reactions;
• severe nausea and vomiting;
• vision problems;
• The decreased levels of serum thyroxine
• Adults can also experience certain side effects after using Saizen 24.i.u.

Some of the side effects are minor:

• Swelling of the hands and feet;
• pain in joints and muscles;
• Headaches;

Some of the major side effects that adults may encounter are:

• severe muscle stiffness;
• Carpal tunnel syndrome;
• Type 2 diabetes;
• severe itching or pain at the injection site;

Glucocorticoids, thyroid hormones, insulin and certain sex steroids have a chance to interact with Saizen 24.i.u. It is recommended that patients be clear with the doctor about other medicines you are taking before buying Saizen 24.i.u.